Get the Stockscreener App
1.23
1.60%
-0.02
After Hours:
1.21
-0.02
-1.63%
Celularity Inc stock is traded at $1.23, with a volume of 14,381.
It is down -1.60% in the last 24 hours and down -6.82% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$1.25
Open:
$1.305
24h Volume:
14,381
Relative Volume:
0.25
Market Cap:
$35.47M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-0.7848
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
+5.13%
1M Performance:
-6.82%
6M Performance:
-59.80%
1Y Performance:
-34.57%
1-Day Range:
$1.20
$1.305
1-Week Range:
$1.20
$1.33
52-Week Range:
$1.01
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.23 | 36.05M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Volume Recap: Can Celularity Inc stock outperform in a bear marketJuly 2025 Closing Moves & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Market Review: Is Celularity Inc Equity Warrant backed by strong institutional buying2025 Big Picture & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Celularity receives $12.2 million from sale of tax credits By Investing.com - Investing.com South Africa
Sell Signal: Is Celularity Inc stock risky to hold now2025 Market Outlook & Low Volatility Stock Recommendations - baoquankhu1.vn
Celularity of Florham Park gets $12.2M from sale of New Jersey net operating losses - ROI-NJ
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - Investing News Network
Celularity receives $12.2 million from sale of tax credits - Investing.com
Celularity Receives $12.2 Million From Sale Of New Jersey Net Operating Losses - TradingView
Celularity Inc. Secures $12.2 Million from Sale of New Jersey Net Operating Losses and R&D Tax Credits - Quiver Quantitative
New Jersey tax program delivers $12.2M boost to Celularity - Stock Titan
Aug Wrap: Is Celularity Inc showing insider buyingJuly 2025 Macro Moves & Growth Focused Stock Reports - baoquankhu1.vn
Loss Report: Will Celularity Inc Equity Warrant benefit from AI trendsGap Down & Technical Pattern Based Buy Signals - baoquankhu1.vn
Highs Report: Why is Celularity Inc stock going upWeekly Earnings Recap & Growth Oriented Trading Recommendations - baoquankhu1.vn
Is Celularity Inc Equity Warrant a top pick in the sector2025 Earnings Surprises & Accurate Technical Buy Alerts - baoquankhu1.vn
Winners Losers: Does Celularity Inc. Equity Warrant have pricing power - baoquankhu1.vn
New Highs: Will Celularity Inc Equity Warrant stock recover after earningsJuly 2025 Outlook & Community Verified Watchlist Alerts - baoquankhu1.vn
Published on: 2026-02-02 09:28:36 - baoquankhu1.vn
Will Celularity Inc. Equity Warrant benefit from AI trendsJuly 2025 Decliners & Low Risk Growth Stock Ideas - mfd.ru
VIX Spike: Does EF Hutton Acquisition Corporation I Equity Warrant have consistent dividend growthJuly 2025 Setups & Weekly High Potential Alerts - baoquankhu1.vn
Volume Summary: What drives Oriental Culture Holding LTDs stock priceJuly 2025 Momentum & Capital Protection Trade Alerts - baoquankhu1.vn
Stock Recap: Will ATYR outperform the market in YEARJuly 2025 Snapshot & Risk Controlled Stock Alerts - baoquankhu1.vn
VIX Spike: What drives Celularity Incs stock priceMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn
Market Trends: Is Celularity Inc Equity Warrant impacted by rising ratesQuarterly Portfolio Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Can Ernexa Therapeutics Inc. be recession proofJuly 2025 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
What is the cash position of Southside Bancshares IncTrade Entry Summary & Community Driven Trade Alerts - baoquankhu1.vn
Movement Recap: Is Celularity Inc a stock for growth or value investors2025 Price Momentum & Weekly Top Performers Watchlists - baoquankhu1.vn
Is Celularity Inc. Equity Warrant stock a smart buy before Fed meetingWatch List & Reliable Entry Point Trade Alerts - Bollywood Helpline
Why Celularity Inc. Equity Warrant stock could rally in 20252025 EndofYear Setup & Safe Capital Preservation Plans - Bollywood Helpline
Downgrade Watch: How does Celularity Inc Equity Warrant perform in inflationary periodsPortfolio Value Report & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Risk On: Will Celularity Inc benefit from government policyJuly 2025 Volume & Long-Term Investment Growth Plans - baoquankhu1.vn
Weekly Earnings: Does Celularity Inc meet Warren Buffetts criteriaWeekly Profit Analysis & Daily Profit Maximizing Tips - baoquankhu1.vn
Volume Report: What is Celularity Inc Equity Warrants revenue forecastJuly 2025 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
Pullback Watch: How Celularity Inc Equity Warrant stock responds to policy changes2025 Winners & Losers & Safe Entry Zone Tips - Bộ Nội Vụ
Revenue Check: What is Celularity Inc Equity Warrants market position2025 Key Highlights & Reliable Intraday Trade Plans - baoquankhu1.vn
Is Celularity Inc. Equity Warrant stock a buy in volatile markets2025 Price Momentum & Accurate Trade Setup Notifications - Улправда
Will Celularity Inc. stock split attract more investorsFootwear buying guidance for recovery days and low impact training focuses on balanced cushioning and support, making it helpful for judging overall value. - ulpravda.ru
Why Celularity Inc. Equity Warrant stock could see breakout soonJuly 2025 Intraday Action & Technical Confirmation Trade Alerts - Улправда
Will Celularity Inc. stock gain from strong economyJuly 2025 Earnings & Technical Pattern Recognition Alerts - Улправда
Celularity receives FDA warning over marketing claims - MSN
Will Celularity Inc. stock outperform tech sector in 2025Stock Price Divergence & Fast Growing Trading Plans - ulpravda.ru
Does Shoora Designs Limited Stock Fit a LongTerm Value StrategyMarket Rumors and News & High Return Stock Ideas - earlytimes.in
Sheppard Mullin Advised Vanterra Ventures, Silo Pharma, Celularity And Others In Recent Deals - Mondaq
Celularity files for offering of up to 14.1 million shares of class A common stock - MarketScreener
Celularity Files for Sale of 14.1 Million Class A Shares - marketscreener.com
Celularity (NASDAQ:CELU) Trading Down 10.4% – Here’s Why - Defense World
Celularity's Biovance, Biovance 3L To Remain Eligible For Med. Coverage Under Withdrawn LCDs - Nasdaq
Aug Outlook: What Wall Street predicts for Celularity Inc Equity Warrant stock price2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - moha.gov.vn
Celularity stock drops after CMS withdraws skin substitute LCDs By Investing.com - Investing.com Australia
Celularity secures new financing to support strategic shift - MSN
Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations - Investing News Network
Celularity stock drops after CMS withdraws skin substitute LCDs - Investing.com
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):